三级淋巴结构在非小细胞肺癌预后及免疫治疗中的研究进展  

Recent Progress of Tertiary Lymphoid Structure in Prognosis and Immunotherapy of Non-small Cell Lung Cancer

作　　者：刘颖[1] 熊磊 蔡若雪 陈越 叶劲军[1] 沈波[1] 周国仁[1] Ying LIU;Lei XIONG;Ruoxue CAI;Yue CHEN;Jinjun YE;Bo SHEN;Guoren ZHOU(The Affiliated Cancer Hospital of Nanjing Medical University,Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research,Nanjing 210009,China;General Hospital of Eastern Theater Command,Nanjing 210002,China)

机构地区：[1]南京医科大学附属肿瘤医院,江苏省肿瘤医院,江苏省肿瘤防治研究所,南京210009 [2]东部战区总医院,南京210002

出　　处：《中国肺癌杂志》2023年第8期615-620,共6页Chinese Journal of Lung Cancer

基　　金：国家自然科学基金项目(No.82273162)资助。

摘　　要：肺癌是当前癌症死亡的首要原因,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)占肺癌的85%。免疫治疗显著改善了NSCLC患者的临床预后,但肿瘤微环境具有复杂性和异质性,仍有部分患者不能受益于免疫治疗,因此有必要探索NSCLC免疫治疗的有效预测生物标志物。三级淋巴结构(tertiary lymphoid structure,TLS)是与次级淋巴器官(secondary lymphoid organs,SLO)高度相似的异位淋巴器官,有研究发现TLS的存在与多种实体瘤(包括NSCLC)免疫治疗的良好预后密切相关。本文对TLS在NSCLC预后及免疫治疗中的作用进行综述,为筛选NSCLC免疫治疗适宜人群及制定个性化、精准化治疗方案提供参考。Lung cancer is the leading cause of cancer death,and non-small cell lung cancer(NSCLC)accounts for 85%.Immunotherapy has significantly improved the clinical prognosis of patients with NSCLC.However,because of the complexity and heterogeneousness of the tumor microenvironment,only a subset of individuals can benefit from immunotherapy.Therefore,it is necessary to explore effective predictive biomarkers for immunotherapy of NSCLC.Tertiary lymphoid structure(TLS)is an ectopic lymphoid organ that is highly similar to secondary lymphoid organs(SLO),and the presence of TLS has been found to be closely associated with a good prognosis in immunotherapy for a variety of solid tumors,including NSCLC.This article provides a review of the prognostic role of tertiary lymphoid structures in immunotherapy of NSCLC,in order to offer references for screening suitable candidates for immunotherapy of NSCLC and develop personalized and precise treatment plans.

关 键 词：三级淋巴结构 肺肿瘤 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]